Slovenian Olympian Katja Fain Reveals Chronic Myeloid Leukemia Diagnosis

When Japanese Olympic swimmer Rikako Ikee was diagnosed with acute lymphoblastic leukemia in 2019, her highly public battle required intense, systemic chemotherapy before her eventual, triumphant return to the Olympic stage. Slovenian swimmer Katja Fain is now facing a different leukemia diagnosis—chronic myeloid leukemia (CML)—and the single respect in which her case differs is that it requires no chemotherapy or radiation. Instead, her condition is managed entirely by a lifelong daily pill. While highly effective for the general population, this targeted therapy presents an entirely undocumented physiological challenge for elite endurance training, leaving her athletic future in uncharted territory.[1][2]

Fain, a 25-year-old two-time Olympian who represented Slovenia at the Tokyo 2020 and Paris 2024 Summer Games, revealed the diagnosis to the public this week. She received the life-altering news on June 30, 2026, a revelation that explained her sudden and previously unexplained withdrawal from the European Championships and the Mediterranean Games earlier this summer. Prior to the diagnosis, Fain had established herself as a versatile force in European swimming, holding 3 individual national records in short course meters and securing a bronze medal in the 200-meter freestyle at the 2021 European Short Course Championships.[1][2][5]

The announcement highlighted the profound psychological shock that accompanies a severe oncological diagnosis in a young, highly conditioned athlete. "My eyes filled with tears, I couldn't understand the words that the doctor was saying as he explained everything to me," Fain wrote in her statement. "I was unable to breathe or speak or even see clearly. I mean, cancer? Me? Why me? I take care of my body, I exercise, I eat right, I don't smoke or drink, I mean, I do everything like you are supposed to, right? But still, life dealt me this card? Why?"[1][3][4]

Chronic myeloid leukemia is a slow-growing blood cancer characterized by a genetic mutation that causes the bone marrow to overproduce abnormal, immature white blood cells. Unlike acute forms of leukemia, CML does not form solid tumors and progresses gradually. The standard of care relies on tyrosine kinase inhibitors (TKIs)—targeted oral medications that specifically attack the cancer cells while sparing healthy tissue. Because it is a chronic condition, patients typically live with it indefinitely, relying on the daily pills to keep the abnormal cell production suppressed and prevent the disease from advancing to a more dangerous acute phase.[1][2]

For the general public, the prognosis following a CML diagnosis is highly optimistic. According to data from Blood Cancer UK cited in the wake of her announcement, most individuals diagnosed with the condition can expect to live a normal lifespan and maintain a high quality of life, provided they strictly adhere to their daily medication regimen. The medical priority is long-term stability rather than an immediate, aggressive cure, transforming what was once a fatal diagnosis into a manageable chronic illness for the vast majority of patients.[1]

However, the implications of this treatment regimen for an elite endurance athlete are entirely unknown. Fain noted that there is "no known elite athlete with this condition in the world," leaving her medical team without any historical precedent or clinical data to draw upon. Because the physiological demands of Olympic-level swimming push the human body to its absolute limits, doctors are currently unable to guarantee that she can safely resume the intense, high-volume training required to compete on the world stage without triggering severe complications.[1][2]

The documented side effects of her oncological medication directly intersect with the specific physiological requirements of her sport. The daily pills can cause systemic fatigue, severe muscle cramps, nausea, and potential complications involving cardiovascular and pulmonary function. For a swimmer whose specialty includes grueling endurance events like the 400-meter individual medley and the 1500-meter freestyle, these side effects present a massive barrier to performance. The medication's impact on oxygen transport and muscle recovery makes traditional elite training protocols potentially hazardous.[2]

Currently, Fain's medical team has strictly prohibited her from executing hard training sessions, all-out sprint efforts, or hypoxic underwater work. She is also barred from all forms of competition for the foreseeable future while her body adjusts to the medication. "This is where my life has been turned upside down, put under a question mark," she explained. "I am living in uncertainty and it is something I am struggling to handle. There is no known case of an elite athlete with this condition in the world and no doctor can tell me that I can safely train intensely every day and nothing will happen."[2]

The immediate medical goal for Fain is to maintain disease stability for several years using the targeted oral therapy. If the medication successfully keeps the cancer "shut down" for an extended period, she may eventually qualify for a treatment-free remission phase. In this scenario, patients can carefully taper off the drugs, though regular blood monitoring remains a lifelong requirement to catch any potential relapse. Fain acknowledged this possibility but noted that she is currently "very far away from even thinking about potentially living a medication-free life."[1][2]

In the near term, the 25-year-old Olympian hopes to return to the water simply for the physical and mental benefits of the sport, rather than for elite international competition. Stripped of the rigorous demands of her previous career, she is focusing on a more fundamental relationship with swimming. "No expectations, no pressure, no stopwatch, just swimming," Fain stated, marking a profound and necessary shift in perspective for an athlete who has spent her entire life racing the clock.[3]